Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00681369 |
Recruitment Status
:
Completed
First Posted
: May 21, 2008
Last Update Posted
: January 24, 2011
|
Sponsor:
AstraZeneca
Information provided by:
AstraZeneca
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date | May 20, 2008 | |||
First Posted Date | May 21, 2008 | |||
Last Update Posted Date | January 24, 2011 | |||
Study Start Date | May 2007 | |||
Primary Completion Date | Not Provided | |||
Current Primary Outcome Measures |
|
|||
Original Primary Outcome Measures | Same as current | |||
Change History | Complete list of historical versions of study NCT00681369 on ClinicalTrials.gov Archive Site | |||
Current Secondary Outcome Measures | Not Provided | |||
Original Secondary Outcome Measures | Not Provided | |||
Current Other Outcome Measures | Not Provided | |||
Original Other Outcome Measures | Not Provided | |||
Descriptive Information | ||||
Brief Title | Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France | |||
Official Title | Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France | |||
Brief Summary | the purpose of this study is to describe the way Faslodex is used in France, in patients suffering from initial breast cancer, that is to evaluate Faslodex treatment duration and to determine patients profile | |||
Detailed Description | Not Provided | |||
Study Type | Observational | |||
Study Design | Observational Model: Cohort Time Perspective: Retrospective |
|||
Target Follow-Up Duration | Not Provided | |||
Biospecimen | Not Provided | |||
Sampling Method | Probability Sample | |||
Study Population | Hospital sample | |||
Condition | Breast Cancer | |||
Intervention | Not Provided | |||
Study Groups/Cohorts | 1
Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007 |
|||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status | Completed | |||
Actual Enrollment |
217 | |||
Original Actual Enrollment | Same as current | |||
Actual Study Completion Date | June 2007 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria | Inclusion Criteria:
|
|||
Sex/Gender |
|
|||
Ages | Child, Adult, Senior | |||
Accepts Healthy Volunteers | No | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | Not Provided | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT00681369 | |||
Other Study ID Numbers | NIS-OFR-FAS-2007/1 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Responsible Party | Francisco Sapunar - Medical Science Director, AstraZeneca | |||
Study Sponsor | AstraZeneca | |||
Collaborators | Not Provided | |||
Investigators |
|
|||
PRS Account | AstraZeneca | |||
Verification Date | January 2011 |